Ipsen Biopharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio

Ipsen Biopharmaceuticals (US): 4 reconciled FDA prescription therapies, $69.4M 2024 CMS Part D & Medicaid spend, and 7 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies4
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2036-01-01
2024 CMS Total Public Spend$69.4M
2024 Medicare Part D Spend$21.8M
2024 Medicaid Spend$47.6M
California HCAI SB 17 Filings7 WAC filings (max 21.6% 2-yr change)